Filtered By:
Specialty: General Medicine
Nutrition: Sodium

This page shows you your search results in order of date.

Order by Relevance | Date

Total 39 results found since Jan 2013.

Evaluation of the effect of sodium zirconium cyclosilicate on arrhythmia-related cardiovascular outcomes in patients receiving chronic haemodialysis with hyperkalaemia: protocol for the multicentre, randomised, controlled DIALIZE-Outcomes study
Introduction Patients with kidney failure receiving chronic haemodialysis have elevated risk of arrhythmias potentially increasing the likelihood of sudden cardiac death, stroke and hospitalisation. The DIALIZE study (NCT03303521) demonstrated that sodium zirconium cyclosilicate (SZC) was an efficacious and well-tolerated treatment for predialysis hyperkalaemia in patients undergoing haemodialysis. The DIALIZE-Outcomes study evaluates the effect of SZC on sudden cardiac death and arrhythmia-related cardiovascular outcomes in patients receiving chronic haemodialysis with recurrent hyperkalaemia. Methods and analysis Intern...
Source: BMJ Open - May 25, 2023 Category: General Medicine Authors: Fishbane, S., Jadoul, M., Dember, L., Kovesdy, C., Al-Shurbaji, A., Lisovskaja, V., Sekar, P., Katona, B., Guzman, N., Herzog, C. Tags: Open access, Renal medicine Source Type: research

Impact of polyethylene glycol loxenatide on cardiovascular outcomes in patients with type 2 diabetes: study protocol for a multicentre, randomised, double-blind, placebo-controlled trial (BALANCE-3)
This study is a multicentre, randomised, double-blind, placebo-controlled trial. Patients with T2DM who fulfilled the inclusion criteria were randomly divided to receive weekly administration of either PEG-Loxe 0.2 mg or placebo (1:1 ratio). The randomisation was stratified according to utilisation of sodium-glucose cotransporter 2 inhibitors, history of CV disease and body mass index. The research period is expected to be 3 years, with a 1-year recruitment period and a 2-year follow-up period. The primary outcome is the occurrence of the first MACE, described as CV death, non-fatal myocardial infarction or non-fatal strok...
Source: BMJ Open - May 16, 2023 Category: General Medicine Authors: Xie, Y., Kuang, J., Li, Q., Hong, T., Ji, L., Kong, Y., Duan, Y., Chen, L. Tags: Open access, Diabetes and Endocrinology Source Type: research

WHO: Nations Must Do More to Reduce Salt Consumption by 2025
In 2013, 194 countries committed to a World Health Organization (WHO) goal of reducing global sodium intake, which in excess can increase people ’s risk of heart disease, stroke, and premature death, by 30% by 2025. A report published by the WHO, however, showed that the world is not on track to meet that target.
Source: JAMA - Journal of the American Medical Association - March 22, 2023 Category: General Medicine Source Type: research

Factors associated with symptomatic intracranial haemorrhage after intravenous thrombolysis in severe white matter lesions: a retrospective analysis
Conclusion Hyperlipidaemia and the NIHSS score before thrombolysis are independent risk factors for bleeding after intravenous thrombolysis in patients with severe WMLs. Delaying the onset of white matter and preventing risk factors for bleeding will help improve the prognosis of cerebral infarction and reduce mortality. These risk factors need to be further evaluated in future studies.
Source: Postgraduate Medical Journal - October 21, 2022 Category: General Medicine Authors: Shen, Y., Li, D., Tang, B., Cao, Q., Hou, Z., Xu, L. Tags: Original research Source Type: research

The unexpected benefits of sodium glucose co-transporter 2 (SGLT2) Inhibitors
N Z Med J. 2022 Aug 19;135(1560):99-104.ABSTRACTThe sodium glucose co-transporter 2 (SGLT2) inhibitor empagliflozin is currently funded in New Zealand for management of patients with type 2 diabetes who have an HbA1c >53mmol/mol and a high cardiovascular (CV) risk. Large clinical trials now provide strong evidence that SGLT2 inhibitors decrease the risk of cardiovascular death, heart failure, progressive kidney dysfunction, myocardial infarction, stroke and gout. Patients with or without diabetes who have a history of heart failure, including those with a preserved left ventricular ejection fraction and patients with ch...
Source: New Zealand Medical Journal - August 24, 2022 Category: General Medicine Authors: Chok G Chan Ralph Stewart Source Type: research

Replacing salt with low-sodium salt substitutes (LSSS) for cardiovascular health in adults, children and pregnant women
CONCLUSIONS: When compared to regular salt, LSSS probably reduce blood pressure, non-fatal cardiovascular events and cardiovascular mortality slightly in adults. However, LSSS also probably increase blood potassium slightly in adults. These small effects may be important when LSSS interventions are implemented at the population level. Evidence is limited for adults without elevated blood pressure, and there is a lack of evidence in pregnant women and people in whom an increased potassium intake is known to be potentially harmful, limiting conclusions on the safety of LSSS in the general population. We also cannot draw firm...
Source: Cochrane Database of Systematic Reviews - August 9, 2022 Category: General Medicine Authors: Amanda Brand Marianne E Visser Anel Schoonees Celeste E Naude Source Type: research

Predictive role of modifiable factors in stroke: an umbrella review
Discussion Diet with rich macronutrients and micronutrients, healthy dietary patterns and favourable physical, emotional health and environmental management should be promoted to decrease the burden of stroke. PROSPERO registration number CRD42021249921.
Source: BMJ Open - June 16, 2022 Category: General Medicine Authors: Wang, X., Liang, M., Zeng, F., Wang, Y., Yang, Y., Nie, F., Shang, M., Ta, N., Wen, L., Ou, L., Yang, Z., Liu, W. Tags: Open access, Neurology Source Type: research

Salt Substitute Cut Disease and Death Rates in Large Trial
A randomized trial recently reported in the New England Journal of Medicine focused on an important question for older adults with high blood pressure or a previous stroke: Can switching from regular salt to a 75% sodium chloride and 25% potassium chloride substitute help protect against stroke, major cardiovascular events, or death?
Source: JAMA - October 26, 2021 Category: General Medicine Source Type: research